Evexia Lifecare Ltd

On 01-Dec, Evexia Lifecare Ltd witnessed a notable uptick in its share price, rising by 5.99% to close at ₹1.77. This gain outpaced the sector's performance and marked a positive intraday movement despite the company’s prolonged fundamental weaknesses and disappointing financial results.

As of 19-Nov, Evexia Lifecare Ltd's stock is priced at Rs. 1.68, down 2.33%, and has reached a 52-week low of Rs. 1.52. The stock has underperformed significantly, declining 51.30% year-to-date, while the Sensex has gained 9.02%.

Evexia Lifecare's historical performance shows significant sales growth from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, despite previous declines. While operating profit improved, profitability metrics decreased, and total liabilities rose, indicating a mixed financial outlook.

Evexia Lifecare's historical performance shows significant fluctuations, with net sales increasing from INR 56.29 crore in March 2024 to INR 110.48 crore in March 2025, despite declines in profit after tax. Overall, the company has experienced a recovery in sales and operating profit, while cash flow remains variable.

The next results date for Evexia Lifecare is 14 November 2025.

As of 28-Oct, Evexia Lifecare Ltd's stock price is 1.76, down 0.56%, with a significant decline of 13.73% over the past week and trading below all major moving averages, indicating a bearish trend. Despite increased investor participation, the stock's year-to-date decline of 48.99% contrasts sharply with the Sensex's gain of 8.30%, reflecting a challenging performance relative to the market.

As of 24-Oct, Evexia Lifecare Ltd's stock price is Rs. 1.86, down 6.06%, marking a new 52-week low and significant underperformance with a year-to-date decline of 46.09%. Despite increased investor participation, the stock remains below all moving averages, indicating a bearish trend amidst a generally positive broader market.

As of October 23, 2025, Evexia Lifecare is considered overvalued with a high PE ratio of 212.41 and an EV to EBITDA ratio of 206.57, significantly contrasting with its peers, and has underperformed the market with a year-to-date decline of 42.61%.

As of October 14, 2025, Evexia Lifecare is considered overvalued with a PE ratio of 214.55 and an EV to EBITDA of 207.60, significantly higher than industry peers like Castrol India and Gulf Oil Lubricants, while also underperforming the Sensex with a year-to-date return of -42.03%.

As of 13-Oct, Evexia Lifecare Ltd's stock price is at 2.04, having risen 0.49% today but down 40.87% year-to-date. Despite a short-term outperformance against the sector, the stock has seen significant declines over the past month and year, raising concerns about investor confidence.

As of October 8, 2025, Evexia Lifecare is considered very expensive and overvalued, with a high PE ratio of 216.70 and poor financial performance metrics, resulting in a -49.50% return over the past year compared to the Sensex's 0.17%.

As of October 6, 2025, Evexia Lifecare is considered overvalued with a PE ratio of 210.26 and a year-to-date return of -43.19%, significantly underperforming compared to its peers and the Sensex.

As of October 3, 2025, Evexia Lifecare is considered very expensive and overvalued, with a PE ratio of 216.70 and a year-to-date return of -41.45%, making it an unfavorable investment compared to its peers.